[On prevention and treatment of arterial hypertension in patients with breast cancer, and undergoing hormonotherapy].
The main purpose of this research was to study an impact of hormonotherapy on changes of the arterial blood pressure in patients with breast cancer. Case histories of 135 patients with the breast cancer and accompanying arterial hypertension (AH) were investigated. According to prescription of hormonotherapy, all patients were divided into two groups. In the first group were included 62 patients; they were treated with 20 mg Tamoxifen. In the second group were included 73 patients; they were treated with 60 mg of Toremifen. In both investigated groups the medicine has been prescribed inside, daily, not less than during two years. Arterial hypertension (AH) was diagnosed when blood pressure was above 140/90 mmHg. In each group there were two subgroups--patients which do not underwent course of treatment for AH and patients which underwent course of treatment for AH. The research revealed that antihypertensive therapy of patients with the breast cancer and accompanying arterial hypertension in most cases allows to prevent progression of AH. Besides, it is necessary to notice that hormonotherapy with Tamoxifen, in comparison with Toremifen, in a greater degree promotes progressing of AH. For antihypertensive treatment Moeksipril was recommended. Monotherapy with Moeksipril showed good antihypertensive effect in patients with mild AH.